About PEMAZYRE — 2 of 3

PEMAZYRE is the first approved, molecularly targeted, oral treatment for FGFR2 fusion-positive CCA

Pemigatinib is a potent inhibitor of FGFR1, 2 and 31,28

  • Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3. It inhibits FGFR phosphorylation and signalling and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements1
  • FGFR2 fusions are strong oncogenic drivers and are the most common FGFR alteration, occurring almost exclusively in 10–16% of iCCA1
Mode of Action Infographic

Adapted from reference 1.